• All Share : 51547.02
    UNCHANGED0.00%
    Top 40 : 4246.45
    UNCHANGED0.00%
    Financial 15 : 15023.67
    UNCHANGED0.00%
    Industrial 25 : 61020.09
    UNCHANGED0.00%

  • ZAR/USD : 11.0795
    UP 0.18%
    ZAR/GBP : 18.0558
    UP 0.36%
    ZAR/EUR : 14.1955
    UP 1.65%
    ZAR/JPY : 0.1017
    UP 0.11%
    ZAR/AUD : 9.9027
    UP 0.12%

  • Gold : 1216.4000
    UP 0.04%
    Platinum : 1339.0000
    UP 0.30%
    Silver : 17.8450
    UP 0.14%
    Palladium : 813.0000
    UP 0.62%
    Brent Crude Oil : 98.390
    UNCHANGED0.00%

  • All data is delayed by 15 min. Data supplied by INET BFA
    Hover cursor over this ticker to pause.

Sat Sep 20 15:59:32 SAST 2014

South Africa awards R5.9 billion HIV drugs supply contracts

Reuters | 29 November, 2012 14:26
HIV infecting a cell (blue). File illustration.
Image by: Gallo Imges/Thinkstock

South Africa on Thursday awarded a R5.9 billion contract to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with its biggest health problem.

Companies that include Aspen Pharmacare, Abbott Laboratories and Adcock Ingram would share the contract, the health department said.

The 5.9 billion rand ($667 million) contract, effective from April next year, aims to increase the number of people on treatment by nearly 50 percent, to 2.5 million next year.

South Africa has nearly 6 million people infected with HIV -- one of the heaviest caseloads in the world. It also has one of largest treatment programmes.

But drug makers are unlikely to rake in big profits from the government award, analysts have ssaid, given the stiff competition in the bidding.

The health department said it saved 2.2 billion rand on the new contract, which it initially expected it would cost 8.1 billion rand.

Aspen Pharmacare, the country's biggest generic drugs maker, was awarded 20 percent of the contract while its closest domestic rival, Adcock Ingram was given 14 percent, the health department said.

Other contracts winners included Chicago-based Abbott Laboratories with 8.1 percent, and domestic firm Cipla Medpro with 9 percent.

SHARE YOUR OPINION

If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.
Sat Sep 20 15:59:32 SAST 2014 ::